Hsp70 promotes antigen-presenting cell function and converts T-cell tolerance to autoimmunity in vivo

10.1038/nm962 ◽  
2003 ◽  
Vol 9 (12) ◽  
pp. 1469-1476 ◽  
Author(s):  
Douglas G Millar ◽  
Kristine M Garza ◽  
Bernhard Odermatt ◽  
Alisha R Elford ◽  
Nobuyuki Ono ◽  
...  
Keyword(s):  
T Cell ◽  
Cell Function ◽  
T Cell Tolerance ◽  
Cell Tolerance ◽  
Antigen Presenting Cell ◽  
Antigen Presenting

T Cell Tolerance and Antigen Presenting Cell Function in the Thymus

1993 ◽  
pp. 159-164 ◽  
Author(s):  
David J. Izon ◽  
John D. Nieland ◽  
Lori A. Jones ◽  
Ada M. Kruisbeek
Keyword(s):  
T Cell ◽  
Cell Function ◽  
T Cell Tolerance ◽  
Cell Tolerance ◽  
Antigen Presenting Cell ◽  
Antigen Presenting

Does T-cell tolerance require a dedicated antigen-presenting cell?

Nature ◽  
1989 ◽  
Vol 338 (6210) ◽  
pp. 74-76 ◽  
Author(s):  
Polly Matzinger ◽  
Sylvie Guerder
Keyword(s):  
T Cell ◽  
T Cell Tolerance ◽  
Cell Tolerance ◽  
Antigen Presenting Cell ◽  
Antigen Presenting

Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance

Blood ◽  
2005 ◽  
Vol 105 (3) ◽  
pp. 1135-1143 ◽  
Author(s):  
Hongwei Wang ◽  
Fengdong Cheng ◽  
Alex Cuenca ◽  
Pedro Horna ◽  
Zheng Zheng ◽  
...  
Keyword(s):  
T Cells ◽  
T Cell ◽  
Imatinib Mesylate ◽  
Tumor Antigens ◽  
Cell Function ◽  
Kinase Inhibitor ◽  
T Cell Tolerance ◽  
Cell Tolerance ◽  
Sti 571 ◽  
Antigen Presenting

Abstract Tumor antigen–specific T-cell tolerance imposes a significant barrier to the development of effective therapeutic cancer vaccines. Bone marrow–derived antigen-presenting cells (APCs) are critical in the induction of this unresponsive state. Here we show that in vitro treatment of APCs with the tyrosine kinase inhibitor, imatinib mesylate (STI-571), enhances the activation of naive antigen-specific T cells and restores the responsiveness of tolerant T cells from tumor-bearing hosts. Furthermore, in vivo treatment with STI-571 not only prevented the induction of tolerance in tumor-specific CD4+ T cells, preserving their responsiveness to a subsequent immunization, but also resulted in enhanced vaccine efficacy. These findings demonstrate that tolerance to tumor antigens is not an insurmountable obstacle and points to modulation of APC function as a promising strategy in the immunotherapy of cancer.

Enhanced Antigen Presenting Cell Function Following in Vivo Priming

1997 ◽  
pp. 189-193
Author(s):  
Geneviève De Becker ◽  
Philippe Mockel ◽  
Jacques Urbain ◽  
Oberdan Leo ◽  
Muriel Moser
Keyword(s):  
Cell Function ◽  
Antigen Presenting Cell ◽  
Antigen Presenting

Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40

10.1038/10503 ◽  
1999 ◽  
Vol 5 (7) ◽  
pp. 780-787 ◽  
Author(s):  
Eduardo M. Sotomayor ◽  
Ivan Borrello ◽  
Erev Tubb ◽  
Frédérique-Marie Rattis ◽  
Harold Bien ◽  
...  
Keyword(s):  
T Cell ◽  
Cd4 T Cell ◽  
T Cell Tolerance ◽  
Cell Tolerance ◽  
T Cell Priming

scholarly journals Deficiency in NOD Antigen-Presenting Cell Function May Be Responsible for Suboptimal CD4+CD25+ T-Cell-Mediated Regulation and Type 1 Diabetes Development in NOD Mice

Diabetes ◽  
2006 ◽  
Vol 55 (7) ◽  
pp. 2098-2105 ◽  
Author(s):  
P. Alard ◽  
J. N. Manirarora ◽  
S. A. Parnell ◽  
J. L. Hudkins ◽  
S. L. Clark ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
T Cell ◽  
Cell Function ◽  
Nod Mice ◽  
Antigen Presenting Cell ◽  
Diabetes Development ◽  
Antigen Presenting

scholarly journals Antigen-presenting cell-targeted lentiviral vectors do not support the development of productive T-cell effector responses: implications for in vivo targeted vaccine delivery

Gene Therapy ◽  
2017 ◽  
Vol 24 (6) ◽  
pp. 370-375 ◽  
Author(s):  
C Goyvaerts ◽  
Y De Vlaeminck ◽  
D Escors ◽  
S Lienenklaus ◽  
M Keyaerts ◽  
...  
Keyword(s):  
T Cell ◽  
Vaccine Delivery ◽  
Lentiviral Vectors ◽  
Antigen Presenting Cell ◽  
Antigen Presenting ◽  
Cell Effector
Sign in / Sign up

Export Citation Format

Share Document